2010年以来美国、澳大利亚和新西兰卵母细胞冷冻周期大幅增加:年轻女性为主,但亟需标准化数据收集
结果显示OC周期数大幅上升(美国+880%,澳新+311%),接受OC的女性平均年龄下降,但返回解冻使用冻存卵母细胞者很少。
要点
- 美国2010—2016年OC周期增加880%,澳新2010—2015年增加311%。
- 美国OC女性平均年龄由2010年36.7岁降至2016年34.7岁。
- 返回解冻者少,且多数解冻周期涉及的卵母细胞冻存不足6个月。
核心结论
- 2010年以来OC周期数大幅增加且接受者趋于年轻化,但返回使用冻存卵母细胞进行治疗的女性很少。
研究设计与样本
- 数据来自美国SART国家登记库和澳大利亚新西兰辅助生殖数据库(ANZARD)。
主要发现
- 美国2010—2016年OC周期增加880%,澳新2010—2015年增加311%。
- 两地多数接受OC的女性为30岁晚期,但平均年龄随时间下降(美国2010年36.7岁 vs 2016年34.7岁)。
- 返回解冻周期数低(美国2016年413个,澳新2015年141个),两地多数解冻周期(47%)涉及的卵母细胞冻存不足6个月。
- 美国仅使用解冻卵母细胞的周期活产比例为25%,联合使用解冻与新鲜卵母细胞的周期为11%(P < 0.001)。
- 美国取卵时年龄影响活产率:≤35岁冻存者38%的解冻周期活产,≥36岁冻存者仅16%活产;澳新无法获得类似数据。
临床怎么用
- 应告知接受OC的女性,目前返回解冻使用冻存卵母细胞的比例很低。
- 咨询时可说明美国数据中冻存时年龄≤35岁与更高解冻后活产率相关。
局限性
- SART与ANZARD数据输出存在局限:ANZARD数据格式及SART数据集周期报告不一致限制了解读。
- 两数据集均未明确OC原因,美国无法准确计算解冻周期的冻存时长。
- 两数据库均未提供胚胎质量详情。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the cohort trends of women undergoing oocyte cryopreservation (OC)? SUMMARY ANSWER: There has been a dramatic increase in OC cycles undertaken each year since 2010, and the demographics of women accessing OC has shifted to a younger age group, but so far very few women have returned to use their cryopreserved oocytes in treatments. WHAT IS KNOWN ALREADY: Although OC, as a method of fertility preservation, is offered around the world, global data are lacking on who is accessing OC, who is returning to thaw oocytes and whether these trends are changing. STUDY DESIGN, SIZE, DURATION: A trinational retrospective cohort study was performed of 31 191 OC cycles and 972 oocyte thaw (OT) cycles undertaken in the USA (2010-2016) and 3673 OC and 517 OT cycles undertaken in Australia/New Zealand (Aus/NZ; 2010-2015). PARTICIPANTS/MATERIALS, SETTING, METHODS: Data were obtained from the USA Society for Assisted Reproductive Technology (SART) national registry and the Australian and New Zealand Assisted Reproduction Database (ANZARD). De-identified data were requested on all autologous oocyte freeze-all cycles and all cycles where autologous oocytes were thawed to be used in a treatment cycle for the time periods of interest. MAIN RESULTS AND THE ROLE OF CHANCE: In both the USA and Aus/NZ, there has been a dramatic rise in the number of OC cycles performed each year (+880% in the USA from 2010 to 2016 and +311% in Aus/NZ from 2010 to 2015). Across both regions, most women undergoing OC were aged in their late 30s, but the average age decreased over time (USA: 36.7 years vs 34.7 years in 2010 and 2016, respectively). The number of women returning for thaw cycles was low (USA: 413 in 2016, Aus/NZ: 141 in 2015) and most thaw cycles (47%) across both regions involved oocytes that were frozen for <6 months. In the USA, a higher proportion of cycles resulted in a live birth when only thawed oocytes were used, compared to cycles that combined thawed oocytes with fresh oocytes (25% vs 11%, respectively; P < 0.001). Age at retrieval influenced live birth rate in the USA; 38% of thaw cycles started in women who stored oocytes when aged ≤35 years resulted in a live birth, whereas only 16% resulted in a live birth for women who stored oocytes when aged ≥36 years. Similar data were unobtainable from Aus/NZ. LIMITATIONS, REASONS FOR CAUTION: There were limitations associated with both the SART and ANZARD data outputs received. The format in which the ANZARD data were provided, and the inconsistencies seen amongst cycle reporting in the SART dataset, restricted data interpretation. For example, both datasets did not provide a clear indication as to why women were undergoing OC and it was not possible to accurately calculate duration of storage for thaw cycles in the USA. We also did not obtain details on embryo quality from either database and acknowledge that embryo quality and subsequent outcome (embryo freezing or discard) would be of interest, especially when considering the efficacy of OC. WIDER IMPLICATIONS OF THE FINDINGS: The data show that there is widespread demand for OC, and it is increasingly undertaken by younger women; however, the limitations encountered in the dataset support the need for a shift to a more uniform approach to data collection and presentation by large databases, worldwide. STUDY FUNDING/COMPETING INTEREST(S): This study received funding from the Fertility Society of Australia to support the ANZARD data extraction. M.J. is supported by an Australian Government Research Training Program Scholarship stipend. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Johnston M, Richings NM, Leung A, et al. A major increase in oocyte cryopreservation cycles in the USA, Australia and New Zealand since 2010 is highlighted by younger women but a need for standardized data collection. Hum Reprod. 2021. PMID: 33367704. doi:10.1093/humrep/deaa320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。